Table 2 Medians and interquartile ranges of assessed parameters at baseline and after 6 months of dupilumab therapy
Initial TPS ≤ 4 | Initial TPS ≥ 5 | Total | |
|---|---|---|---|
TPS | |||
Baseline | 3 [1–4] | 6 [6–7] | 4 [2–6] |
Month 6 | 0 [0–0] | 2 [1–4] | 0 [0–1] |
SNOT-22 | |||
Baseline | 36.5 [23.5–58.8] | 52 [35–65] | 40 [28–61.5] |
Month 6 | 9.5 [5.5–16] | 9.5 [7.3–12] | 9.5 [6–14.8] |
Sniffin´ sticks | |||
Baseline | 6 [3–11] | 4 [3–4] | 4 [3–9] |
Month 6 | 10 [7–12] | 12 [9–12.3] | 11 [8–12] |
EQ-5D-3L | |||
Baseline | 6 [5–7] | 6 [5–7] | 6 [5–7] |
Month 6 | 5 [5–5] | 5 [5–6] | 5 [5–6] |
PHQ-2 | |||
Baseline | 1 [0–2] | 2 [0–2] | 1 [0–2] |
Month 6 | 0 [0–1] | 0 [0–0] | 0 [0–0.8] |
ACT | |||
Baseline | 23 [19–24] | 19 [14.5–21] | 22 [18.5–24] |
Month 6 | 25 [24–25] | 24 [22–25] | 25 [23–25] |
Mini AQLQ | |||
Baseline | 5.9 [4.5–6.5] | 4.5 [3.8–5.6] | 5.6 [4.1–6.3] |
Month 6 | 6.7 [6.5–6.9] | 6.6 [5.9–6.9] | 6.7 [6.4–6.9] |